We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The retrospective analysis included 26 clinical studies ...

Severe asthma treatment with the interleukin-5 antagonist mepolizumab (Nucala) reduced the need to take oral corticosteroids in patients who had depended on steroids to control symptoms, according to ...

Please provide your email address to receive an email when new articles are posted on . Researchers divided this patient population into those with vs. without chronic bronchitis at baseline. More ...

While mepolizumab has proven safe and effective for severe asthma, how has it performed in treating those with allergic vs non-allergic asthma? Mepolizumab use significantly reduced the use of oral ...

Researchers compared the effectiveness of 3 biologics for moderate to severe asthma in an observational study and found superior improvement with dupilumab. Dupilumab was associated with higher ...

SAN ANTONIO -- Treatment with the interleukin-5 (IL-5) antagonist mepolizumab (Nucala) increased freedom from oral corticosteroids after 2 years in patients with severe eosinophilic asthma, according ...

Compared with placebo, the time to first moderate or severe exacerbation was longer with mepolizumab. HealthDay News — For patients with chronic obstructive pulmonary disease (COPD) with a history of ...

Nucala is the only approved biologic studied in a wide COPD population with an eosinophilic phenotype characterized by blood eosinophil count (BEC) starting at 150 cells/μL Approval based on the ...